Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
SZSE:002932.SZ
21.72 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 749.537 | 10,530.278 | 2,829.83 | 959.099 | 181.155 | 176.381 | 165.123 | 140.979 | 95.342 | 57.802 | 25.947 | 7.096 | 1.218 |
Cost of Revenue
| 342.703 | 3,491.17 | 707.026 | 208.995 | 46.514 | 40.386 | 29.951 | 20.392 | 20.065 | 16.632 | 7.631 | 2.924 | 0.463 |
Gross Profit
| 406.834 | 7,039.108 | 2,122.803 | 750.104 | 134.641 | 135.995 | 135.173 | 120.587 | 75.277 | 41.17 | 18.317 | 4.172 | 0.755 |
Gross Profit Ratio
| 0.543 | 0.668 | 0.75 | 0.782 | 0.743 | 0.771 | 0.819 | 0.855 | 0.79 | 0.712 | 0.706 | 0.588 | 0.62 |
Reseach & Development Expenses
| 141.415 | 388.36 | 132.745 | 69.932 | 36.956 | 27.104 | 25.613 | 20.981 | 8.737 | 3.369 | 2.159 | 0 | 0 |
General & Administrative Expenses
| 38.933 | 30.208 | 25.418 | 10.466 | 6.7 | 7.45 | 4.581 | 4.282 | 6.604 | 1.735 | 3.853 | 1.507 | 0.728 |
Selling & Marketing Expenses
| 115.945 | 450.772 | 197.66 | 92.34 | 47.013 | 37.069 | 28.762 | 24.117 | 16.188 | 11.907 | 5.927 | 1.153 | 0.146 |
SG&A
| 154.879 | 480.979 | 223.078 | 102.806 | 53.714 | 44.518 | 33.343 | 28.399 | 22.792 | 13.642 | 9.781 | 2.66 | 0.874 |
Other Expenses
| -5.305 | 146.002 | 54.39 | 12.661 | 9.457 | 2.535 | -0.238 | 2.016 | 0.274 | 2.443 | 0.324 | 0.366 | 0.536 |
Operating Expenses
| 306.693 | 1,015.341 | 410.213 | 185.399 | 100.126 | 71.01 | 61.037 | 54.274 | 34.831 | 19.019 | 10.101 | 2.737 | 0.893 |
Operating Income
| 145.194 | 5,079.833 | 1,697.814 | 562.279 | 41.538 | 68.298 | 75.664 | 67.095 | 41.216 | 22.265 | 8.314 | 1.275 | -0.245 |
Operating Income Ratio
| 0.194 | 0.482 | 0.6 | 0.586 | 0.229 | 0.387 | 0.458 | 0.476 | 0.432 | 0.385 | 0.32 | 0.18 | -0.201 |
Total Other Income Expenses Net
| -5.305 | -3.436 | -3.257 | -5.578 | 5.016 | 5.848 | 1.291 | 2.797 | 1.044 | 2.735 | 0.422 | 0.122 | 0.377 |
Income Before Tax
| 139.889 | 5,076.397 | 1,694.557 | 556.701 | 46.554 | 70.833 | 75.426 | 69.11 | 41.49 | 24.886 | 8.638 | 1.557 | 0.239 |
Income Before Tax Ratio
| 0.187 | 0.482 | 0.599 | 0.58 | 0.257 | 0.402 | 0.457 | 0.49 | 0.435 | 0.431 | 0.333 | 0.219 | 0.197 |
Income Tax Expense
| 70.673 | 695.926 | 247.869 | 81.073 | 4.047 | 8.365 | 9.872 | 9.418 | 5.894 | 3.347 | 1.316 | 0.155 | -0.014 |
Net Income
| 74.926 | 4,208.497 | 1,413.224 | 468.928 | 41.526 | 61.42 | 65.493 | 59.692 | 35.597 | 21.54 | 7.322 | 1.402 | 0.253 |
Net Income Ratio
| 0.1 | 0.4 | 0.499 | 0.489 | 0.229 | 0.348 | 0.397 | 0.423 | 0.373 | 0.373 | 0.282 | 0.198 | 0.208 |
EPS
| 0.33 | 18.08 | 6.68 | 2.27 | 0.2 | 0.35 | 0.42 | 0.39 | 0.23 | 0.15 | 0.85 | 0.39 | 0.004 |
EPS Diluted
| 0.33 | 18.08 | 6.68 | 2.27 | 0.2 | 0.35 | 0.42 | 0.39 | 0.23 | 0.15 | 0.85 | 0.39 | 0.004 |
EBITDA
| 304.09 | 6,152.89 | 1,741.628 | 580.941 | 63.975 | 85.409 | 85.47 | 70.826 | 42.066 | 25.911 | 8.807 | 1.812 | 0.399 |
EBITDA Ratio
| 0.406 | 0.584 | 0.615 | 0.606 | 0.353 | 0.484 | 0.518 | 0.502 | 0.441 | 0.448 | 0.339 | 0.255 | 0.328 |